LGND Ligand Pharmaceuticals Inc

Price (delayed)

$79.745

Market cap

$1.43B

P/E Ratio

14.63

Dividend/share

N/A

EPS

$5.45

Enterprise value

$1.39B

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
The debt has plunged by 93% YoY
Ligand Pharmaceuticals's net income has soared by 85% from the previous quarter
The revenue has declined by 42% year-on-year and by 10% since the previous quarter
The gross profit has declined by 28% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
17.96M
Market cap
$1.43B
Enterprise value
$1.39B
Valuations
Price to book (P/B)
1.75
Price to sales (P/S)
11.95
EV/EBIT
11.37
EV/EBITDA
8.74
EV/Sales
11.74
Earnings
Revenue
$118.31M
EBIT
$122.13M
EBITDA
$158.8M
Free cash flow
-$16.89M
Per share
EPS
$5.45
Free cash flow per share
-$0.95
Book value per share
$45.55
Revenue per share
$6.67
TBVPS
$29.17
Balance sheet
Total assets
$913.87M
Total liabilities
$107.35M
Debt
$6.19M
Equity
$806.52M
Working capital
$351.1M
Liquidity
Debt to equity
0.01
Current ratio
20.7
Quick ratio
19.03
Net debt/EBITDA
-0.28
Margins
EBITDA margin
134.2%
Gross margin
91.8%
Net margin
81.4%
Operating margin
0.6%
Efficiency
Return on assets
11.9%
Return on equity
13.6%
Return on invested capital
35.1%
Return on capital employed
13.6%
Return on sales
103.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
-0.08%
1 week
-0.39%
1 month
-8.34%
1 year
3.75%
YTD
11.66%
QTD
9.09%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$118.31M
Gross profit
$108.64M
Operating income
$725,000
Net income
$96.34M
Gross margin
91.8%
Net margin
81.4%
The net margin has soared by 105% from the previous quarter
The company's operating income has shrunk by 95% YoY and by 94% QoQ
Ligand Pharmaceuticals's operating margin has shrunk by 93% QoQ and by 92% YoY
Ligand Pharmaceuticals's net income has soared by 85% from the previous quarter

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
14.63
P/B
1.75
P/S
11.95
EV/EBIT
11.37
EV/EBITDA
8.74
EV/Sales
11.74
Ligand Pharmaceuticals's EPS has surged by 80% QoQ
LGND's P/E is 60% below its last 4 quarters average of 36.4
The equity has grown by 25% year-on-year and by 15% since the previous quarter
LGND's P/B is 20% lower than its 5-year quarterly average of 2.2 but 2.9% higher than its last 4 quarters average of 1.7
The revenue has declined by 42% year-on-year and by 10% since the previous quarter
The price to sales (P/S) is 41% higher than the last 4 quarters average of 8.5 and 20% higher than the 5-year quarterly average of 10.0

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's return on sales has surged by 182% YoY and by 116% QoQ
The ROA has soared by 78% QoQ
The company's return on equity has surged by 74% QoQ
Ligand Pharmaceuticals's ROIC has soared by 68% from the previous quarter and by 36% YoY

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
Ligand Pharmaceuticals's quick ratio has surged by 57% QoQ
LGND's current ratio is up by 46% since the previous quarter
The debt is 99% less than the equity
The debt has plunged by 93% YoY
The debt to equity has plunged by 93% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.